New hope for advanced breast cancer: experimental drug AC699 enters human testing

NCT ID NCT05654532

Ongoing Disease control Sponsor: Accutar Biotechnology Inc Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times

Summary

This early-phase study tests a new drug, AC699, in about 100 people with a common type of advanced breast cancer (ER+/HER2-). The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors or slow the cancer's growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 01

Nashville, Tennessee, 37203, United States
Site 02

Sarasota, Florida, 34232, United States
Site 03

Houston, Texas, 77030, United States
Site 04

Vancouver, Washington, 98684, United States
Site 05

Norfolk, Virginia, 23502, United States
Site 06

Rockville, Maryland, 21044, United States
Site 07

Orlando, Florida, 32746, United States
Site 08

Denver, Colorado, 80218, United States
Site 09

San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER